Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on Magnesium Homeostasis
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 10
- 主要终点
- Effects of EGFR inhibitors on magnesium homeostasis
研究概览
简要总结
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving epidermal growth factor receptor inhibitors may help doctors understand the effect of epidermal growth factor receptor inhibitors on magnesium levels in the body.
PURPOSE: This laboratory study is looking at the effect of epidermal growth factor receptor inhibitors on magnesium homeostasis in patients with cancer.
详细描述
OBJECTIVES:
- Determine the effects of EGFR inhibitors on magnesium homeostasis in patients with cancer.
OUTLINE: This is a pilot study.
Patients undergo blood and urine sample collection at baseline and at 2, 4, and 8 weeks during treatment.
After finishing treatment, patients are followed periodically for up to 10 weeks.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of malignancy
- •Planning to receive therapy with an inhibitor of the EGFR pathway (either on or off a clinical trial and may be monotherapy or combined with other therapies)
- •Normal serum magnesium level
排除标准
- •Glomerular filtration rate ≥ 60 mL/min
- •No severe underlying renal dysfunction
- •Normal serum potassium and calcium level
- •No history of primary or secondary hyperparathyroidism
- •PRIOR CONCURRENT THERAPY:
- •No prior EGFR pathway inhibitor
结局指标
主要结局
Effects of EGFR inhibitors on magnesium homeostasis
时间窗: 8 weeks
次要结局
未报告次要终点
研究者
Laura W. Goff, MD
Assistant Professor of Medicine; Associate Director, Hematology/Oncology
Vanderbilt-Ingram Cancer Center